Article
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Antimicrobial agents and chemotherapy - 1 Mar 2010
Moya Bartolome, Zamorano Laura, Juan Carlos, Pérez José L, Ge Yigong, Oliver Antonio
Abstract excerpt
CXA-101, previously designated FR264205, is a new antipseudomonal cephalosporin. We evaluated the activity of CXA-101 against a highly challenging collection of beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit (ICU) patients. The in vitro mutants investigated included strains with multiple combinations of mutations leading to several...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.